Square Pharmaceuticals PLC. (DSE:SQURPHARMA)

Market Cap	200.07B +3.8%
Revenue (ttm)	81.95B +13.4%
Net Income	25.95B +16.0%
EPS	29.27 +16.0%
Shares Out	886.45M
PE Ratio	7.71
Forward PE	7.00
Dividend	12.00 (5.32%)
Ex-Dividend Date	Nov 17, 2025

Volume	701,328
Average Volume	949,818
Open	227.00
Previous Close	226.10
Day's Range	225.20 - 227.00
52-Week Range	198.00 - 236.00
Beta	0.05
RSI	60.10
Earnings Date	Apr 29, 2026

About DSE:SQURPHARMA

Square Pharmaceuticals PLC., together with its subsidiaries, manufactures, markets, and distributes pharmaceutical products in Bangladesh and internationally. The company offers pharmaceutical products comprising alimentary preparations, amoebocides, analgesics, anthelmintics, anti-aphthous ulcer, anti-erectile dysfunction, anti-gout, anti-hyperkalemia, anti-osteoarthritis, anti-thyroid, anti-ulcerants, antiallergies, antianemics, antiasthma, antibiotics, antidiabetics, antifibrinolytics, antihemorrhoidals, antihistamines, antiosteoporotics, an...

• Industry: Pharmaceutical Preparations
• Founded: 1958
• Employees: 15,937
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: SQURPHARMA

Financial Performance

In fiscal year 2025, DSE:SQURPHARMA's revenue was 76.29 billion, an increase of 8.83% compared to the previous year's 70.10 billion. Earnings were 23.97 billion, an increase of 14.54%.